Table 1.
Characteristics of Included Studies
| Author, year | Inclusion Criteria | Diagnostic Status | Duration | Treatment Group, (No. of Participants) | Age Range | Outcomes |
|---|---|---|---|---|---|---|
| Chaudhry, 201417 | SZ, SA, P-NOS, SF | DSM-IV | 12 weeks | Simvastatin 20–40mg/day (11)/Placebo (12) | 18–65 | PANSS total, positive, negative, and general,CGI, GAF |
| Sommer, 202111 | SZ, SA, P-NOS, SF | DSM-IV | 48 weeks | Simvastatin 40mg/day (56)/Placebo (48) | 18–50 | PANSS total, positive, negative, and general,GAF |
| Tajik-Esmaeeli, 201618 | SZ | DSM-IV-TR | 8 weeks | Simvastatin 40mg/day (33)/Placebo (33) | 18–60 | PANSS total, positive, negative, and general |
| Weiser, 202312 | SZ, SA | DSM-IV-TR | 12 weeks | Simvastatin 40mg/day (116)/Placebo (116) | 18–65 | PANSS total, positive, negative, and general,CGI |
Abbreviations: PANSS, Positive and Negative Syndrome Scale; DSM-(TR), Diagnostic and Statistical Manual of Mental Disorders (Text Revision); SZ, schizophrenia; SA, schizoaffective disorder; P-NOS, psychosis not otherwise specified; SF, schizophreniform disorder; CGI, Clinical Global Impression; GAF, Global Assessment of Functioning.